OptiNose

OptiNose P/FCF

Delisted

The P/FCF (Price-to-Free-Cash-Flow Ratio) of OptiNose (OPTN) as of Nov 11, 2026 is -2.16. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -4.66 — a change of -53.60% (higher).

P/FCF

-2.16

YoY

-53.60%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of OptiNose is 2024 -2.16 . P/FCF (Price-to-Free-Cash-Flow Ratio) of OptiNose was 2023 -4.66 . It decreases by -53.60% higher compared to the previous year.

The OptiNose P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2017
-2.55 USD
Jan 1, 2018
-1.04 USD
Jan 1, 2019
-1.06 USD
Jan 1, 2020
-1.12 USD
Jan 1, 2021
-1.26 USD
Jan 1, 2022
-1.44 USD
Jan 1, 2023
-4.66 USD
Jan 1, 2024
-2.16 USD
The OptiNose P/FCF history
YEARP/FCFYoY
-2.16-53.60%
-4.66+224.61%
-1.44+13.86%
-1.26+12.52%
-1.12+5.33%
-1.06+2.34%
-1.04-59.30%
-2.55-156.51%
4.52-233.89%
-3.38—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OptiNose Stock analysis

What does OptiNose do? OptiNose, Inc. develops and commercializes pharmaceutical products for ear, nose, and throat specialists and allergy specialists. The company's lead product, XHANCE (fluticasone propionate) nasal spray, uses a breath powered exhalation delivery system to treat chronic rhinosinusitis with nasal polyps. XHANCE is marketed as a topically acting anti-inflammatory corticosteroid that delivers medication directly to the site of inflammation. The company also has product candidates including XHANCE for chronic sinusitis, OPN-300, and OPN-021, which are part of its pipeline for ENT and allergy treatments. XHANCE is the company's primary revenue-generating product, targeting ENT and allergy specialists who prescribe it to patients with chronic rhinosinusitis and nasal polyps. The product's differentiated clinical profile positions it as a potential standard of care in its therapeutic area. Other pipeline products like OPN-300 and OPN-021 are in development but not yet commercialized, so they do not contribute to current revenue streams. The company's business model relies on the commercialization of XHANCE, which is sold to healthcare providers and patients through pharmaceutical distribution channels. ENT and allergy specialists are the key buyers of XHANCE, as it is designed specifically for their patient populations. The company's focus on nasal polyps and chronic sinusitis treatments aligns with the needs of these medical specialists. OptiNose is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OptiNose stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of OptiNose is -2.16 in 2024.

P/FCF (Price-to-Free-Cash-Flow Ratio) of OptiNose changed from -4.66 to -2.16, representing a -53.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) OptiNose since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s OptiNose with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — OptiNose

All Key Metrics — OptiNose